{"protocolSection": {"identificationModule": {"nctId": "NCT03962101", "orgStudyIdInfo": {"id": "263-102-00004"}, "secondaryIdInfos": [{"id": "JapicCTI-194715", "type": "OTHER", "domain": "JapicCTI"}], "organization": {"fullName": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}, "briefTitle": "Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake", "officialTitle": "A Multicenter, Open-label, Uncontrolled Clinical Trial to Confirm the Tolerability of OPC-61815 in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake"}, "statusModule": {"statusVerifiedDate": "2021-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-06-17", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-06-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-06-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-04-18", "studyFirstSubmitQcDate": "2019-05-22", "studyFirstPostDateStruct": {"date": "2019-05-23", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-07-15", "resultsFirstSubmitQcDate": "2021-08-09", "resultsFirstPostDateStruct": {"date": "2021-09-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-08-09", "lastUpdatePostDateStruct": {"date": "2021-09-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To confirm the tolerability of intravenous administration of OPC-61815 at 8 or 16 mg once daily for a maximum of 5 days to CHF patients with volume overload despite having received diuretics (injection) other than vasopressin antagonists and who have difficulty with or are incapable of oral intake."}, "conditionsModule": {"conditions": ["Congestive Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 45, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "OPC-61815 injection", "type": "EXPERIMENTAL", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.", "interventionNames": ["Drug: OPC-61815 injection"]}], "interventions": [{"type": "DRUG", "name": "OPC-61815 injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.", "armGroupLabels": ["OPC-61815 injection"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs", "description": "\"An AE is defined as any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an AE that leads to death, is life-threatening, results in persistent or significant disability/incapacity, requires in-patient or prolonged hospitalization, results in a congenital anomaly/birth defect, or any other important medical event which is medically significant.\n\nA TEAE is an AE that occurs only after a subject has received IMP.", "timeFrame": "From the start of IMP administration (Day 1) up to 15 days"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Body Weight", "description": "Change in body weight from baseline (before IMP administration on Day 1) at time of final IMP administration (day after final IMP administration). A negative change from baseline indicates improvement.", "timeFrame": "Baseline, Day after final IMP administration"}, {"measure": "Improvement Rate for Lower Limb Edema", "description": "The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated", "timeFrame": "Baseline, Day after final IMP administration"}, {"measure": "Improvement Rate for Pulmonary Congestion", "description": "The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated", "timeFrame": "Baseline, Day after final IMP administration"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients receiving loop diuretic injection at a dose equivalent to furosemide 20 mg/day or higher\n* CHF patients in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present\n* Patients who are judged by the investigator or subinvestigator to have difficulty or be incapable of oral intake, including patients who are judged by the investigator or subinvestigator to require nothing by mouth(NPO) management\n* Patients who are currently hospitalized or who are capable of being hospitalized from the time of informed consent until the end of the treatment period\n* Patients who are capable of giving informed consent\n\nExclusion Criteria:\n\n* Patients who are on a ventricular assist device\n* Patients who have difficulty with spontaneous respiration or who have been on tracheal intubation under sedative therapy\n* Patients with severe disturbed consciousness (ie, coma or stupor)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Takehisa Matsumaru", "affiliation": "Otsuka Pharmaceutical Co., Ltd.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Gifu Prefectural General Medical Center", "city": "Gifu", "country": "Japan", "geoPoint": {"lat": 35.42291, "lon": 136.76039}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 45 subjects were administered investigational medicinal product (IMP): 38 subjects with dose maintained at 8 mg, and 7 subjects with dose increased to 16 mg. None of the subjects reduced the dose after the dose was increased to 16 mg. All 45 subjects received at least one dose of IMP and thus were included in the safety analysis set. Overall, 41 subjects completed the trial (34 of those subjects completed the trial early), and 4 subjects were discontinued from the trial.", "groups": [{"id": "FG000", "title": "OPC-61815 Injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Not related to medical events", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Analysis Set: subjects who received at least one dose of IMP", "groups": [{"id": "BG000", "title": "OPC-61815 Injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "45"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "73.7", "spread": "11.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs", "description": "\"An AE is defined as any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an AE that leads to death, is life-threatening, results in persistent or significant disability/incapacity, requires in-patient or prolonged hospitalization, results in a congenital anomaly/birth defect, or any other important medical event which is medically significant.\n\nA TEAE is an AE that occurs only after a subject has received IMP.", "populationDescription": "Safety Analysis Set: subjects who received at least one dose of IMP", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From the start of IMP administration (Day 1) up to 15 days", "groups": [{"id": "OG000", "title": "OPC-61815 Injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight", "description": "Change in body weight from baseline (before IMP administration on Day 1) at time of final IMP administration (day after final IMP administration). A negative change from baseline indicates improvement.", "populationDescription": "Subjects with both baseline and evaluation of the given parameter at the specific visit.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline, Day after final IMP administration", "groups": [{"id": "OG000", "title": "OPC-61815 Injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.01", "lowerLimit": "-3.79", "upperLimit": "-2.23"}]}]}]}, {"type": "SECONDARY", "title": "Improvement Rate for Lower Limb Edema", "description": "The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated", "populationDescription": "Efficacy Analysis Set: subjects who received at least one dose of IMP and had at least one postbaseline dose efficacy measurement.\n\n\"Overall Number of Participants Analyzed\" = number of subjects with baseline symptoms.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Day after final IMP administration", "groups": [{"id": "OG000", "title": "OPC-61815 Injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "73.7", "lowerLimit": "56.9", "upperLimit": "86.6"}]}]}]}, {"type": "SECONDARY", "title": "Improvement Rate for Pulmonary Congestion", "description": "The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated", "populationDescription": "Efficacy Analysis Set: subjects who received at least one dose of IMP and had at least one postbaseline dose efficacy measurement.\n\n\"Overall Number of Participants Analyzed\" = number of subjects with baseline symptoms.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Day after final IMP administration", "groups": [{"id": "OG000", "title": "OPC-61815 Injection", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81.8", "lowerLimit": "67.3", "upperLimit": "91.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "TEAEs were collected from the start of IMP administration up to 15 days", "description": "Subjects who received at least one dose of IMP were included in the safety analysis.", "eventGroups": [{"id": "EG000", "title": "OPC-61815 Injection Maintained at 8 mg", "description": "Intravenous administration of OPC-61815 at 8 mg once daily for a maximum of 5 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 38, "seriousNumAffected": 2, "seriousNumAtRisk": 38, "otherNumAffected": 22, "otherNumAtRisk": 38}, {"id": "EG001", "title": "OPC-61815 Injection Increased to 16 mg", "description": "Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8 mg, increase the dose to 16 mg on Day 2 and onward, according to the dose escalation criteria.", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 2, "otherNumAtRisk": 7}], "seriousEvents": [{"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}], "otherEvents": [{"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Haematochezia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Injection site inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 7}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Delirium", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 7}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Dry skin", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}, {"term": "Phlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 38}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 7}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director of Clinical Trials", "organization": "Otsuka Pharmaceutical Co., LTD.", "email": "CL_OPCJ_RDA_Team@otsuka.jp", "phone": "+81-3-6361-7366"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-04-17", "uploadDate": "2021-07-15T21:11", "filename": "Prot_000.pdf", "size": 1040309}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-09-10", "uploadDate": "2021-07-15T21:12", "filename": "SAP_001.pdf", "size": 2103945}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}